What is the rationale for tapering prednisone doses?

What is the rationale for tapering prednisone doses?

• A. Sudden discontinuation of the medication may result in adrenal insufficiency.
• B. The patient would experience withdrawal symptoms if the drug were discontinued abruptly.
• C. Cushing's syndrome may develop as a reaction to a sudden drop in serum cortisone levels.
• D. When the symptoms have started to disappear, lower dosages are needed.

Answer: (A)

Tapering prednisone is needed to prevent adrenal insufficiency that can occur when the body’s own cortisol production is suppressed by long-term steroid use. When prednisone is taken for an extended period, the hypothalamic-pituitary-adrenal (HPA) axis reduces its own cortisol output. If the medication is stopped suddenly, there isn’t enough endogenous cortisol available to meet the body’s needs, which can lead to an adrenal crisis with symptoms like low blood pressure, weakness, dizziness, nausea, and possible shock. Gradually lowering the dose gives the adrenal glands time to recover and resume normal cortisol production, reducing the risk of life-threatening insufficiency and withdrawal symptoms. Withdrawal symptoms can occur with abrupt cessation, but the key danger is adrenal crisis rather than just discomfort. Cushing’s syndrome arises from excessive steroid exposure, not from stopping a dose abruptly. And tapering is about allowing physiological recovery of the HPA axis, not solely based on the observed disappearance of symptoms.

Tapering prednisone is needed to prevent adrenal insufficiency that can occur when the body’s own cortisol production is suppressed by long-term steroid use. When prednisone is taken for an extended period, the hypothalamic-pituitary-adrenal (HPA) axis reduces its own cortisol output. If the medication is stopped suddenly, there isn’t enough endogenous cortisol available to meet the body’s needs, which can lead to an adrenal crisis with symptoms like low blood pressure, weakness, dizziness, nausea, and possible shock. Gradually lowering the dose gives the adrenal glands time to recover and resume normal cortisol production, reducing the risk of life-threatening insufficiency and withdrawal symptoms.

Withdrawal symptoms can occur with abrupt cessation, but the key danger is adrenal crisis rather than just discomfort. Cushing’s syndrome arises from excessive steroid exposure, not from stopping a dose abruptly. And tapering is about allowing physiological recovery of the HPA axis, not solely based on the observed disappearance of symptoms.